Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

被引：0
|
作者：
Patel, Aarat M. [1 ]
Lupash, Daniel [1 ]
Chew, Douglas [1 ]
Levesque, Marc C. [1 ]
Moreland, Larry W. [1 ]
机构：
[1] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15261 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2011年 / 13卷 / 05期
关键词：
Cost-effectiveness; Incremental cost-effectiveness ratios; Cost-utility analysis; Biologics; Biologic agents; DMARDs; Quality-adjusted life-years; Rheumatoid arthritis;
D O I：
10.1007/s11926-011-0197-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：381 / 382
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Aarat M. Patel
    Daniel Lupash
    Douglas Chew
    Marc C. Levesque
    Larry W. Moreland
    [J]. Current Rheumatology Reports, 2011, 13 : 381 - 382
  • [2] COST-EFFECTIVENESS OF BIOLOGICS COMPARED TO CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN FINLAND
    Joensuu, J. T.
    Aaltonen, K. J.
    Aronen, P.
    Sokka, T.
    Puolakka, K.
    Tuompo, R.
    Korpela, M.
    Vasala, M.
    Ilva, K.
    Nordstrom, D.
    Blom, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A648 - A648
  • [3] Cost-Effectiveness of Biologic Response Modifiers Compared to Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Systematic Review
    van der Velde, Gabrielle
    Pham, Ba'
    Machado, Marcio
    Ieraci, Luciano
    Witteman, William
    Bombardier, Claire
    Krahn, Murray
    [J]. ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 65 - 78
  • [4] Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China
    Tian, Feng
    Wen, Zhenhua
    Li, Jingyang
    Luo, Xiaowen
    Deng, Li
    Zhang, Liang
    He, Jingyun
    Yao, Fangling
    Liao, Zheng
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (14)
  • [5] Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice
    Kuijper, T. Martijn
    Buisman, Leander R.
    Hazes, Johanna M.
    Weel, Angelique E.
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (07) : 965 - 967
  • [6] Cost-Effectiveness of Biologics in Polyarticular-Course Juvenile Idiopathic Arthritis Patients Unresponsive to Disease-Modifying Antirheumatic Drugs
    Ungar, Wendy J.
    Costa, Vania
    Hancock-Howard, Rebecca
    Feldman, Brian M.
    Laxer, Ronald M.
    [J]. ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 111 - 119
  • [7] COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) COMPARED TO STANDARD OF CARE IN SINGAPORE
    Chua, J. N.
    Lahiri, M.
    Cheung, P. P.
    Yoong, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 834 - 835
  • [8] Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
    Michael T. Nurmohamed
    Ben A. C. Dijkmans
    [J]. Drugs, 2005, 65 : 661 - 694
  • [9] Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis
    Nurmohamed, MT
    Dijkmans, BAC
    [J]. DRUGS, 2005, 65 (05) : 661 - 694
  • [10] Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis
    Combe, Bernard
    [J]. JOINT BONE SPINE, 2006, 73 (06) : 587 - 590
12345